Lonza (LONN.SW) Financial Analysis & Valuation | Quarter Chart
Lonza (LONN.SW)
LONN.SWPrice: $696.98
Fair Value: 🔒
🔒score
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract develo... more
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets... more
Description
Shares
| Market Cap | $48.89B | Exchange | SIX |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | CH | CEO | Wolfgang Wienand |
| IPO Date | 1999-11-01 | CAGR | 0.05% |
| Employees | 17,995 | Website | www.lonza.com |
| Div. Yield | 1% | Payout Ratio | 0.31% |
| Buy Back Yield | 4.38% | Total Yield | 5.38% |
LONN.SW chart loading...
Fundamentals
Technicals
| Enterprise Value | $4.08B | P/E Ratio | 41.37 |
| Forward P/E | 23.29 | PEG Ratio | — |
| P/S Ratio | 4.33 | P/B Ratio | 3.1 |
| P/CF Ratio | 24.45 | P/FCF Ratio | -133.86 |
| EPS | $16.85 | EPS Growth 1Y | -11.74% |
| EPS Growth 3Y | 17.28% | EPS Growth 5Y | 127.13% |
| Revenue Growth 1Y | 1.28% | Gross Margin | 0.35% |
| Operating Margin | 0.21% | Profit Margin | 0.14% |
| ROE | 0.1% | ROA | 0.05% |
| ROCE | 0.09% | Current Ratio | 2.24 |
| Quick Ratio | 1.77 | Cash Ratio | 0.2 |
| Debt/Equity | 0.46 | Interest Coverage | 8.22 |
| Altman Z Score | 4.4 | Piotroski Score | 7 |